Spinal Cord Injury and Stem Cell Therapy in Thailand

This is the condition where the gap between what people hope for and what has been shown is widest, and where the cost of an unrealistic expectation is highest. Spinal cord injury and stem cell therapy has a real research literature — several systematic reviews — and no established treatment, and both halves of that sentence matter.

What the injury actually is

Damage to the spinal cord interrupts the pathways carrying signals between brain and body. Below the level of injury, movement, sensation and autonomic function are affected to a degree depending on how complete the damage is.

Two phases matter. The primary injury is the mechanical damage at the moment of trauma. The secondary injury unfolds over hours to weeks — swelling, inflammation, reduced blood supply and cell death extending the damage beyond the original site.

That second phase is where most experimental intervention is aimed, because the first is already over by the time anyone arrives.

Chronic injury, months or years later, is a different problem again: the acute cascade has finished and what remains is a scarred, established lesion.

What established care provides

Acute surgical decompression and stabilisation where indicated, and intensive management of blood pressure and oxygenation to limit secondary injury.

Then rehabilitation, which is where the functional gains genuinely come from — physiotherapy, occupational therapy, and increasingly activity-based training and functional electrical stimulation.

Management of the complications that shorten lives in this population: pressure injury, urinary tract infection, autonomic dysreflexia, spasticity and pain.

None of this is glamorous and all of it is evidenced. Any cell therapy discussion sits alongside it rather than in place of it.

Why cells are being studied here

Several proposed mechanisms, none demonstrated in humans: limiting the secondary injury cascade by modulating inflammation, supporting surviving neurons, encouraging remyelination of axons that are intact but non-functional, and modifying the glial scar.

Notice that none of these is “growing a new spinal cord”. Even the optimistic version of the hypothesis is about preserving and supporting what remains.

That distinction is rarely made in marketing aimed at this group, and it is the difference between a plausible research direction and a promise nobody can keep — see MSC immunomodulation.

What the reviews found

A 2023 systematic review assessed MSC therapy in traumatic spinal cord injury — Mesenchymal Stem Cell Therapy in Traumatic Spinal Cord Injury: A Systematic Review.

An earlier systematic review examined the current evidence base — Current evidence on mesenchymal stem cell therapy for traumatic spinal cord injury: systematic review — and a 2024 review looked specifically at chronic injury — Systematic Review of Cell Therapy Efficacy in Human Chronic Spinal Cord Injury.

A 2024 study assessed safety and potential efficacy of expanded MSCs from bone marrow and umbilical cord — Safety and potential efficacy of expanded mesenchymal stromal cells of bone marrow and umbilical cord — and a 2022 study used an intramedullary route — Efficacy and outcome of bone marrow derived stem cells transplanted via intramedullary route.

Read the titles carefully. “Safety and potential efficacy” is a phase-appropriate description of early work, not a result.

What those reviews do not show

That any patient walked who would not otherwise have walked. No controlled trial has demonstrated that.

Most included studies are small, many are uncontrolled, and outcome measures differ between them. Spontaneous recovery occurs in incomplete injuries during the first year, which makes uncontrolled results in that window nearly uninterpretable.

Follow-up is short relative to a lifelong condition, and publication bias in a field this emotionally charged is a genuine concern.

The timing question

Acute and chronic injury are different targets. Most of the mechanistic rationale applies to the acute and subacute phase, when the secondary cascade is still running.

But acute patients are in hospital, unstable, and not in a position to travel. The people who travel for treatment are almost all chronic — months or years post-injury — which is where the rationale is weakest.

That mismatch is structural, and it is worth stating plainly rather than leaving a reader to discover it.

Routes, and why they matter more here

Intravenous infusion is least invasive and least likely to deliver cells anywhere near the lesion. Intrathecal injection places cells in the spinal fluid. Intramedullary injection places them into the cord itself, which is a neurosurgical procedure with corresponding risk.

The studies above use different routes, and pooling them obscures a real difference in both risk and plausibility.

Anyone offering an intravenous infusion for spinal cord injury should be asked which published study supports that route specifically — see MSC therapy.

Risks worth weighing carefully

Beyond the general risks, this population faces specific ones: procedures around an already-damaged cord, infection risk in people who are often catheterised, and the possibility of worsening neuropathic pain or spasticity.

There is also a documented risk in this field of tumour formation following unregulated cell injection into the nervous system. It is rare and it has happened — see adverse events.

And the opportunity cost is larger here than anywhere else on this site: money spent on an unproven infusion is money not spent on rehabilitation, equipment or home adaptation, all of which reliably improve daily life.

What we would say to someone considering this

That the research is genuine and ongoing, that no treatment has been established, and that a registered clinical trial is a more defensible route than a commercial infusion.

That anyone quoting recovery stories is quoting the cases that recovered, and you are not being shown the ones that did not.

And that if a review of your records concludes there is nothing worth offering, we will say so — see the patient journey and what the evidence levels mean.

Nerve damage and neuropathy covers peripheral nerve injury, which — unlike the cord — can regrow, and where the human evidence is correspondingly better.

Frequently asked questions

Requesting a medical evaluation

Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.

Message us on WhatsApp

This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.